<DOC>
	<DOCNO>NCT00402597</DOCNO>
	<brief_summary>The purpose study evaluate safety rivaroxaban patient recent acute coronary syndrome ( ACS ) ass ability rivaroxaban reduce occurrence death , myocardial infarction ( heart attack ) , repeat myocardial infarction , stroke , ischemia ( inadequate blood supply local area ) patient recent ACS .</brief_summary>
	<brief_title>Rivaroxaban Combination With Aspirin Alone With Aspirin Thienopyridine Patients With Acute Coronary Syndromes ( The ATLAS ACS TIMI 46 Trial )</brief_title>
	<detailed_description>This randomize ( patient assign study treatment chance ) , double-blind ( neither patient study doctor know identity assign study treatment ) study evaluate safety efficacy rivaroxaban ( study drug ) compare placebo ( tablet identical appearance study drug contains active drug ) patient acute coronary syndrome ( ACS [ condition blood flow blood vessel heart restrict blood clot ] ) . Rivaroxaban drug act blood thinner test see safe effective patient diagnose ACS . The goal study identify dose dosing schedule ( once-a-day twice-a-day dosing ) rivaroxaban safe effective prevent adverse cardiovascular outcome death , myocardial infarction ( MI ) include repeat myocardial infarction ( reMI ) , stroke , ischemia ( inadequate blood supply local area ) require revascularization ( ie , re-establishment blood supply part organ ) patient ACS receive antiplatelet therapy ( ie , aspirin alone aspirin plus approved thienopyridine , type drug clopidogrel act inhibit formation blood clot ) . Approximately 3500 patient plan participate study approximately 7 month . At study entry , patient currently receive treatment ACS antiplatelet therapy permit continue therapy study . Patients enrol randomized receive placebo , rivaroxaban administer once-daily dose , rivaroxaban administer twice-daily dose dose level rivaroxaban test . Patients randomize dose level continue receive treatment 6 month . Near end enrollment first dose level , available safety efficacy data patient assess Operations Committee enrol randomize additional patient next high dose level rivaroxaban . Increasing dose level rivaroxaban plan ; however , progression high dose level discretion Operations Committee . Patient safety monitor evaluate adverse event report , result clinical laboratory test , finding electrocardiograms ( ECGs ) vital sign measurement , finding physical examination , number patient protocol-defined major minor bleeding , bleed require medical attention . All patient take study drug placebo tablet orally ( mouth ) twice daily 6 month start initial total daily dose 5 mg . Both once- twice-daily dosing regimen test rivaroxaban dose level plan .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Have symptom suggestive ACS last least 10 minute rest occur within 7 day randomization Have diagnosis STelevation myocardial infarction nonST elevation myocardial infarction/unstable angina ( ie , chest pain discomfort ) ( ST elevation abnormal finding ECG test ) least 1 protocoldefined high risk feature Active bleeding high risk bleed intracranial hemorrhage ( bleed within skull enclose brain ) Need continue anticoagulant therapy Significantly impaired renal ( kidney ) hepatic ( liver ) function Severe concomitant diseases cardiogenic shock ( heart damage result insufficient blood supply part organ body ) , refractory ventricular arrhythmia ( irregular contraction heart unresponsive treatment ) , severe condition would limit life expectancy patient le 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Acute Coronary Syndrome ( ACS )</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Rivaroxaban ( BAY59-7939 )</keyword>
	<keyword>Anti-platelet agent</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Thienopyridine</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>